BioAesthetics is a technology company.
BioAesthetics has raised $6.0M across 1 funding round.
BioAesthetics has raised $6.0M in total across 1 funding round.
BioAesthetics is a medtech company developing tissue-engineered biomaterials for reconstructive surgeries, primarily targeting breast cancer reconstruction.[1][2] Its flagship product, the NACgraft, is an acellular tissue-engineered nipple-areolar complex (NAC) graft that serves as a scaffold for patients' bodies to regenerate natural, living nipple and areola tissue post-mastectomy, addressing a critical need for breast cancer survivors.[1] The company serves plastic and reconstructive surgeons, solving the problem of unnatural, prosthetic-based nipple reconstruction by enabling biological regeneration.[1][3] Founded in 2015 and headquartered in Durham, North Carolina, BioAesthetics has raised $7.35M in grants, remaining in an early "Grant - II" stage with steady progress in biomaterial innovation.[1]
BioAesthetics was founded in 2015 in Durham, North Carolina, emerging from the need to advance biomaterials in reconstructive surgery, particularly for breast cancer patients.[1] While specific founders are not detailed in available sources, the company originated with a focus on tissue engineering and regenerative medicine, leveraging expertise in biomaterial development to create life-enhancing products.[2][3] Early traction came through grants from investors like the National Science Foundation, NCBiotech Industrial Internship Program, IndieBio, SOSV, and New Orleans BioInnovation Center, totaling $7.35M, which supported R&D for its core NACgraft technology.[1] Pivotal moments include filing three patents in areas like cell biology and invertebrate toxins, signaling technical maturation.[1]
BioAesthetics rides the wave of regenerative medicine and biomaterials, a booming sector in medtech driven by rising cancer survivorship—over 4 million U.S. breast cancer survivors—and demand for personalized, biological solutions over synthetic implants.[1][2] Timing aligns with advances in tissue engineering, accelerated post-2020 by biotech funding surges and FDA pushes for innovative reconstruction options amid mastectomy rates holding steady at ~100,000 annually in the U.S. Market forces like aging populations, precision medicine trends, and insurer preferences for durable outcomes favor its scaffold tech.[3][4] By influencing reconstructive standards, it contributes to the ecosystem's shift toward "living" implants, potentially inspiring applications in other areas like pelvic reconstruction.[1][4]
BioAesthetics is poised for clinical trials and FDA clearance of NACgraft, with next steps likely including scaled manufacturing and partnerships with surgical centers to drive adoption.[1] Trends like AI-optimized biomaterials and expanded regenerative therapies for oncology will shape its path, potentially unlocking pelvic and other reconstruction markets.[4] Its grant-backed, patent-protected model could evolve into Series A funding or acquisition by medtech giants, amplifying impact on patient quality of life while riding medtech's 8-10% CAGR through 2030—transforming reconstruction from cosmetic fix to biological restoration.[1][2]
BioAesthetics has raised $6.0M in total across 1 funding round.
BioAesthetics's investors include Atomic, Babel Ventures, ExSight Capital Management, Incite Ventures, Mayfield, Offline Ventures, Refactor Capital, Social Starts, SOSV, SV Angel, Y Combinator, Sam Altman.
BioAesthetics has raised $6.0M across 1 funding round. Most recently, it raised $6.0M Series A in October 2020.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Oct 1, 2020 | $6.0M Series A | Atomic, Babel Ventures, ExSight Capital Management, Incite Ventures, Mayfield, Offline Ventures, Refactor Capital, Social Starts, SOSV, SV Angel, Y Combinator, Sam Altman |